The dysregulation, overexpression or genetic alterations of hypoxia-inducible factor 1-alpha, also known as HIF-1α, have been profoundly associated with cancer biology, which qualifies HIF-1α as a therapeutically valuable target in cancer therapy [132]. This evidence concerns the gene HIF1A and cancer.